Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
An announcement from Shanghai Junshi Biosciences Co., Ltd. Class H ( (HK:1877) ) is now available.
Shanghai Junshi Biosciences Co., Ltd. announced the election of Dr. Yang Jin as an Independent Non-executive Director, effective September 29, 2025. This change also affects the composition of the Remuneration and Appraisal Committee and the Nomination Committee, with Dr. Yang Jin and Ms. Lu Kun taking new roles. The abolishment of the Board of Supervisors marks a significant shift in the company’s governance structure, potentially impacting its operational and strategic direction.
The most recent analyst rating on (HK:1877) stock is a Hold with a HK$34.70 price target. To see the full list of analyst forecasts on Shanghai Junshi Biosciences Co., Ltd. Class H stock, see the HK:1877 Stock Forecast page.
More about Shanghai Junshi Biosciences Co., Ltd. Class H
Shanghai Junshi Biosciences Co., Ltd. is a joint stock company incorporated in the People’s Republic of China, operating in the biosciences industry. The company focuses on the development and commercialization of innovative therapies, particularly in the field of immunotherapy.
Average Trading Volume: 13,139,562
Technical Sentiment Signal: Buy
Current Market Cap: HK$42B
For a thorough assessment of 1877 stock, go to TipRanks’ Stock Analysis page.